Research Candidates

 
News Articles for Research Candidates top ^
2013/2/28
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the U.S. Food and Drug Administration (FDA) has designated the company’s late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI). Additionally, the company received from the FDA notification that Cubist’s antibiotic candidates, ceftolozane/tazobactam and surotomycin, have been granted Fast Track status in their previously granted QIDP indications, Complicated Intra-Abdominal Infections (cIAI) and Clostridium difficile -Associated Diarrhea (CDAD) respectively.
Sign-up for FDA Grants QIDP and Fast Track Designations for Cubist’s Late-Stage Antibiotic Candidates investment picks
2013/5/6
Patent Covers Composition of Matter and Uses for Various Cancers ROCKVILLE, Md.
Sign-up for Patent Issued In China For EntreMed's Lead Drug Candidate ENMD-2076 investment picks
2013/5/8
Medicago successfully produces VLP vaccine candidate for H7N9 virus responsible for recent influenza outbreak in China Canada NewsWire -Medicago Ready to Collaborate with Authorities to Further Study the Potential of this Vaccine to Protect Against H7N9- QUEBEC CITY, May 8, 2013 /CNW/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully produced a new VLP vaccine candidate  for the H7N9 virus that is responsible for the current influenza outbreak in China .
Sign-up for Medicago successfully produces VLP vaccine candidate for H7N9 virus responsible for recent influenza outbreak in China investment picks
2013/2/15
FOX News Channel (FNC) has hired former Republican presidential candidate, businessman, author and columnist Herman Cain as a contributor, announced Bill Shine, Executive Vice President of Programming.
Sign-up for FOX News Channel Signs Former Presidential Candidate Herman Cain to Contributor Role investment picks
2013/3/14
Arrowhead Research Corporation (NASDAQ: ARWR) , a targeted therapeutics company, today announced that a study of its RNAi-based candidate ARC-520 in a chimpanzee chronically infected with the human hepatitis B virus (HBV) supports findings from rodent models indicating that it can knock down HBV DNA and key viral antigens.
Sign-up for Arrowhead RNAi Candidate ARC-520 Induces Greater than 90% Reduction in Circulating HBV DNA in Chimpanzee with Chronic Hepatitis B investment picks
2013/3/28
DANBURY, Conn., March 28, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced the completion of patient enrollment in a Phase 2 clinical study of ultra-rapid-acting prandial insulin candidate BIOD-123 for the treatment of diabetes.
Sign-up for Biodel Completes Enrollment in Phase 2 Clinical Trial of Ultra-Rapid-Acting Insulin Candidate BIOD-123 for the Treatment of Diabetes investment picks
2013/4/8
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has initiated a Phase 2 clinical program for SPI-2012 (also referred to as “LAPS-GCSF”), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes partner Hanmi Pharmaceutical Company’s proprietary LAPSCOVERY™ Technology.
Sign-up for Spectrum Pharmaceuticals Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for the Treatment of Chemotherapy-Induced Neutropenia investment picks
2013/4/10
New Pre-Clinical Data Presented at AACR Annual Meeting in Washington, DC SAN DIEGO , April 10, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP) , an oncology company focused on the clinical development of novel therapies for cancer, announced the presentation of new data showing the ability of its mitochondrial inhibitor drug candidate, ME-344, to decrease tumor burden and delay recurrence in a pre-clinical in vivo model of recurrent epithelial ovarian cancer, the most lethal of all gynecologic malignancies.
Sign-up for MEI Pharma's Mitochondrial Inhibitor Drug Candidate ME-344 Delays Tumor Growth In Recurrent Ovarian Cancer Model investment picks
2013/4/22
NanoViricides, Inc. (OTC BB: NNVC ) (the "Company") said it anticipates that the oral and injectable FluCide™ drug candidates would be effective against the novel H7N9 strain that has caused human fatalities in China in recent months.
Sign-up for NanoViricides Anticipates FluCide™ Drug Candidates to be Effective Against H7N9 investment picks
2013/4/29
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that it has presented results from studies that demonstrate efficacy of two next-generation antibiotic candidates against community-acquired multi-drug resistant (MDR) infections.
Sign-up for Tetraphase Presents Data at ECCMID Supporting Efficacy of Two Antibiotic Candidates Against Multi-Drug Resistant Infections investment picks
2013/5/7
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product (QIDP) indications, Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI). The FDA granted Fast Track status for ceftolozane/tazobactam in Complicated Intra-Abdominal Infections (cIAI) in February 2013.
Sign-up for FDA Grants Fast Track Designation for Cubist’s Late-Stage Antibiotic Candidate investment picks
2013/5/8
-Medicago Ready to Collaborate with Authorities to Further Study the Potential of this Vaccine to Protect Against H7N9- QUEBEC CITY, May 8, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully produced a new VLP vaccine candidate  for the H7N9 virus that is responsible for the current influenza outbreak in China .
Sign-up for Medicago successfully produces VLP vaccine candidate for H7N9 virus responsible for recent influenza outbreak in China investment picks
2013/5/13
Dell Inc. (DELL) shareholders Carl Icahn and Southeastern Asset Management Inc. named the twelve candidates they would propose for the computer company's board of directors, including the billionaire investor Mr.
Sign-up for Icahn, Southeastern Name 12 Board Candidates for Dell investment picks
2013/3/7
Arrowhead Research Corporation (NASDAQ: ARWR) , a targeted therapeutics company, today announced that it will host an analyst and investor event on Monday, March 25, from 12:30 to 2:00 p.m. EST in New York City.
Sign-up for Arrowhead to Host Analyst Event in New York to Discuss RNAi-based Hepatitis B Candidate ARC-520 investment picks
2013/2/28
CHICAGO , Feb.
Sign-up for CareerBuilder Makes It Easy for Employers to Capture Job Candidates on Mobile Devices investment picks
2013/2/19
NanoViricides, Inc. (OTC: NNVC ) (the "Company"), has filed its quarterly report with the Securities and Exchange Commission on Thursday, February 14th, in a timely fashion.
Sign-up for NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Phase I Clinical Trials of its First Drug Candidate investment picks
2013/2/4
Data were published in The Lancet today from a Phase IIb clinical trial evaluating the safety and efficacy of MVA85A in preventing tuberculosis (TB) in infants.
Sign-up for Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet investment picks
2013/2/26
Arrowhead Research Corporation (NASDAQ: ARWR) , a targeted therapeutics company, today announced the publication of data demonstrating multi-log reductions in hepatitis B viral DNA and proteins lasting over 30 days after a single injection in animal models.
Sign-up for Arrowhead Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B Virus investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Research Candidates
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Campus  |  Next: Research Capabilities